Resverlogix Corp.: Expert Panel Reviews Resverlogix Corp. ApoA-I Enhancing Technologies
14th Nov 2006, 18:04 GMT
CHICAGO, ILLINOIS (MARKET WIRE)
Resverlogix Corp.: Expert Panel Reviews Resverlogix Corp. ApoA-I Enhancing Technologies related news:
- F.D.A. to Seek Advice of Expert Panel on Safety of Sanof-Aventis Drug — NYT > Business
- Amazing Technologies Corp. Completes a Definitive Agreement to Acquire Atlantic Technologies Spa, a Leading JD Edwards IT Services Consultant Based in Italy — ArriveNet : Press Releases
- Operator panel features 15in display — Control and Instrumentation latest news on Engineeringtalk
- MedaSorb Technologies Corp Files New Patent Application — StratWire - Business of Healthcare NewsFeed
- Amazing Technologies Corp.: Amazing Technologies Corp. Completes a Definitive Agreement to Acquire Atlantic Technologies Spa, a Leading JD Edwards IT Services Consultant Based in Italy — Market Wire - Computers and Software
- Utek deal lights the way for LEDs — bizjournals.com Real Estate:Commercial headlines
- Railpower Technologies Corp.: Railpower Reports 2006 Third Quarter Financial Results and Steps to Improve Liquidity — Market Wire - Professional Services
- House panel to examine terms of Lucent-Alcatel deal — News -- SiliconValley.com
- United Technologies lands $30M jet engine Air Force contract — bizjournals.com Manufacturing:General headlines
- A new Expert from Peugeot — Automotoportal.com RSS
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech